Introducing ViraxVet™

Virax vet logo

We at Virax Biolabs are pleased to announce the launch of our new ViraxVet™ range, positioning us at the forefront of the diagnosis of viral diseases in animals. With the introduction of our ViraxVet™ range, Virax Biolabs are expanding our footprint in the diagnostics space.

This range is just the latest addition to our portfolio of high quality, cost effective in-vitro diagnostics (IVD). Building upon our success from our ViraxClear platform for human IVDs, we have carefully assembled a diverse portfolio of PCR and antigen based diagnostic kits designed specifically for diagnosing animal diseases. Here are some key areas that make ViraxVet™ a great solution.

PCR: A Gold Standard for Veterinary Medicine:

Polymerase Chain Reaction (“PCR”) technology has rapidly evolved to become the gold standard in human diagnostics, and we at Virax Biolabs are harnessing its power for veterinary medicine. By adapting this technology for animal disease diagnostics, the tests in our ViraxVet™ range bring unparalleled accuracy and efficiency to veterinarians and researchers alike.

Comprehensive and Multiplex Diagnostic Solutions:

Our ViraxVet™ range offers a diverse array of PCR and antigen based test kits catering to different animal groups. We cover the areas of small animals (pets), horses, and farm livestock, addressing a wide range of veterinary needs. Our meticulously curated product line ensures we provide reliable and targeted solutions for diagnosing animal diseases.

ViraxVet™ tests are available in multiplex real-time PCR and antigen formats, enabling the simultaneous detection of multiple pathogens within a single sample. This advancement significantly streamlines the diagnostic process, saving valuable time and resources for veterinarians. By providing multiplex testing capabilities, we empower veterinary professionals to identify co-infections or complex disease patterns, leading to more accurate diagnoses and tailored treatment plans.

Targeted Pathogens:

Our ViraxVet™ range includes PCR and antigen-based test kits that target either a single infectious pathogen or a combination of pathogens. These kits have been specifically designed to address the diagnostic needs of veterinarians caring for various animal species, from household pets to farm animals. We have carefully selected tests for use with Canine, Feline, Equine, Porcine, and Bovine animals, ensuring comprehensive coverage across different species commonly encountered in veterinary practice.

We hope that these our comprehensive range of ViraxVet™ tests will provide quick and accurate disease detection, leading to improved animal welfare, targeted treatments, and effective disease control measures.

At Virax Biolabs, we are dedicated to advancing animal disease diagnostics through our ViraxVet™ range. By offering multiplex real-time PCR and antigen tests, we are providing veterinarians with the convenient tools they need to approach diagnosis. With our comprehensive range of targeted test kits for different animal species, we want to empower veterinary professionals around the world. The ViraxVet™ range opens up new possibilities in animal healthcare by ensuring that professionals can spend their time working on better health outcomes for our beloved pets, horses, and farm livestock.

Caution Concerning Forward Looking Statements: This blog post contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this blog post and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. These forward-looking statements are based on information currently available to Virax and its current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the “Risk Factors” section of Virax’s Annual Report on Form 20-F for the year ended March 31, 2022. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this blog post and other statements made from time to time by us or our representatives might not occur.

Media and Investor Contact:

  • Nic Johnson and Adanna Alexander
  • Russo Partners, LLC
  • +1 (303) 482-6405